Belarus Pharmaceuticals and Healthcare Report Q2 2016

75 pages report Published in
Pharmaceuticals
Publisher: Business Monitor International

arrowFor This Report

BMI View: Government initiatives to boost the nascent domestic pharmaceutical industry and reduce the
reliance on imports will limit the attractiveness of Belarus to multinational drugmakers. Government
interference, in the form of domestic bias in the medicine tendering process and pricing controls, will
further reduce revenue earning opportunities. Additional risks include a continued poor economic forecast
and rising regional geopolitical tensions.
Headline Expenditure Projections
Pharmaceuticals: BYR12,247bn in 2015 (USD801mn) to BYR14,219bn (USD783mn) in 2016; +16.1% in
local currency terms and -2.1% in US dollar terms.
Healthcare: BYR60,885bn (USD3.98bn) in 2015 to BYR71,906bn (USD3.96bn) in 2016; +18.1% in local
currency terms and -0.4% in US dollar terms.

Table of Contents

BMI Industry View 7
Table: Headline Pharmaceuticals & Healthcare Forecasts (Belarus 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Belarus 2012-2020) 13
Healthcare Market Forecast 14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Belarus 2012-2020) 16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Belarus 2012-2020) 16
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Belarus 2012-2020) 17
Prescription Drug Market Forecast 18
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Belarus 2012-2020) 19
Patented Drug Market Forecast 20
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Belarus 2012-2020) 21
Generic Drug Market Forecast 22
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Belarus 2012-2020) 24
OTC Medicine Market Forecast 25
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Belarus 2012-2020) 26
Pharmaceutical Trade Forecast 27
Table: Pharmaceutical Trade Data And Forecasts (Belarus 2014-2020) 29
Table: Pharmaceutical Trade Data And Forecasts local currency (Belarus 2014-2020) 29
Industry Risk Reward Index 30
Central And Eastern Europe Risk/Reward Index 30
Belarus Risk/Reward Index 36
Rewards 36
Risks 37
Regulatory Review 39
Intellectual Property Issues 41
Pricing And Reimbursement Regime 42
Market Overview 45
Healthcare Sector 46
Table: Healthcare Resources (Belarus 2010-2015) 49
Table: Healthcare Personnel (Belarus 2010-2015) 49
Table: Healthcare Activity (Belarus 2010-2015) 50
Research And Development 50
Clinical Trials 51
Epidemiology 52
Competitive Landscape 56
Research-Based Industry 56
Table: Multinational Market Activity 57
Generic Drugmakers 58
Pharmaceutical Distribution 59
Pharmaceutical Retail Sector 60
Company Profile 61
Lekpharm 61
Demographic Forecast 64
Demographic Outlook 64
Table: Population Headline Indicators (Belarus 1990-2025) 65
Table: Key Population Ratios (Belarus 1990-2025) 65
Table: Urban/Rural Population & Life Expectancy (Belarus 1990-2025) 66
Table: Population By Age Group (Belarus 1990-2025) 66
Table: Population By Age Group % (Belarus 1990-2025) 67
Glossary 69
Methodology 71
Pharmaceutical Expenditure Forecast Model 71
Healthcare Expenditure Forecast Model 71
Notes On Methodology 72
Risk/Reward Index Methodology 73
Index Overview 74
Table: Pharmaceutical Risk/Reward Index Indicators 74
Indicator Weightings 75

List of Tables

Table: Headline Pharmaceuticals & Healthcare Forecasts (Belarus 2014-2020)
Table: Pharmaceutical Sales, Historical Data And Forecasts (Belarus 2012-2020)
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Belarus 2012-2020)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Belarus 2012-2020)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Belarus 2012-2020)
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Belarus 2012-2020)
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Belarus 2012-2020)
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Belarus 2012-2020)
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Belarus 2012-2020)
Table: Pharmaceutical Trade Data And Forecasts (Belarus 2014-2020)
Table: Pharmaceutical Trade Data And Forecasts local currency (Belarus 2014-2020)
Table: Healthcare Resources (Belarus 2010-2015)
Table: Healthcare Personnel (Belarus 2010-2015)
Table: Healthcare Activity (Belarus 2010-2015)
Table: Multinational Market Activity
Table: Population Headline Indicators (Belarus 1990-2025)
Table: Key Population Ratios (Belarus 1990-2025)
Table: Urban/Rural Population & Life Expectancy (Belarus 1990-2025)
Table: Population By Age Group (Belarus 1990-2025)
Table: Population By Age Group % (Belarus 1990-2025)
Table: Pharmaceutical Risk/Reward Index Indicators

Related Reports

  • Belarus Pharmaceuticals and Healthcare Report Q3 2016BMI View: Belarus poses challenges for multinational drugmakers given government initiatives to reduce the reliance on medicinal imports. The weak ruble has seen prices of foreign medicines rise to unaffordable levels and has led to state intervention in the form of domestic bias in the medicine tendering process, pricing controls and initiatives to boost the domestic drug-making industry. The poor economic outlook further deepens the risk to revenue earning opportunities. Headline […]
  • Kuwait Pharmaceuticals and Healthcare Report Q3 2015BMI View: While the losses incurred by Yiaco, the largest drug distributor in Kuwait, highlight a deteriorated near-term operating environment, with markedly lower prices as a result of the ongoing Gulf Cooperation Council (GCC) medicine price unification process, drugmakers will continue to perceive high long-run returns. Exhibiting a high and very costly burden of diabetes and cardiovascular conditions, Kuwait's aging population will continue to receive rising access to quality […]
  • China Pharmaceuticals and Healthcare Report Q2 2015BMI View: Pharmaceutical sales in China will continue to grow robustly - boosted by the improvement in healthcare access, liberalisation of the industry as well as an epidemiological transition towards chronic diseases. This will present strong revenue earning opportunities for both domestic and multinational pharmaceutical companies. However, downside risks to this upbeat outlook remain as the government will face pressures to contain medicine costs. Headline Expenditure […]
  • Australia Pharmaceuticals and Healthcare Report Q2 2016BMI View: As the Australian government continues to focus on cost containment while at the same time increasing the population's access to innovative medicines, companies will increasingly need to justify the price of their treatments by demonstrating their value to the broader healthcare system in improving the quality of life. This will need to be further substantiated by rigorous economic analysis which showcases a strong incremental product cost effectiveness ratio. Headline […]
  • Bulgaria Pharmaceuticals and Healthcare Report Q2 2016BMI View: Bulgaria's healthcare sector is in need of reform to improve its efficiency; however, it is likely to see spending cuts as the government must enforce strong cost-saving measures to reduce the budget deficit. Such controls to healthcare spending will produce a bleak outlook for pharmaceutical and healthcare providers. Headline Expenditure Projections ? Pharmaceuticals: BGN2.71bn (USD1.52bn) in 2015 to BGN2.89bn (USD1.58bn) in 2016; +6.7% in local currency terms and +3.8% in […]